Ethnicity-Influenced Microbiota: A Future Healthcare Perspective

Dehingia, Madhusmita; Adak, Atanu; Khan, Mojibur R.

doi:10.1016/j.tim.2019.01.002

Cited by 10 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, several targeted metabolomic approaches had been carried out in the last years, most of them focusing only on lipidomics or analyzing just a few metabolites [22]. However, as microbiome is highly modified by several factors including ethnicity, diet and lifestyle [15,16], the obtained results are not necessarily applicable worldwide. Each population may have a personalized signature of NAFLD biomarkers, which makes it necessary to develop local studies, especially in South America where prevalence of disease is the highest [4].…”

Section: Discussionmentioning

confidence: 99%

“…Each human’s gut microbiome differs due to enterotypes, body mass index (BMI) level, exercise frequency, lifestyle and cultural and dietary habits [15]. In addition, the gut microbiome differs among ethnicities [16] and thus, it would be of interest to study the presence of patterns that may contribute to a higher NAFLD prevalence or different disease severity in Latin America, where data is still scarce.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease in Argentina

Mazzini

Cook²,

Gorcsan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and Aims: Non-invasive biomarkers are urgently needed to identify patients with non-alcoholic fatty liver disease (NAFLD) especially those at risk of disease progression. This is particularly true in high prevalence areas such as Latin America. The gut microbiome and intestinal permeability may play a role in the risk of developing NAFLD and NASH, but the mechanism by which microbiota composition disruption (or dysbiosis) may affect NAFLD progression is still unknown. Targeted metabolomics is a powerful technology for discovering new associations between gut microbiome-derived metabolites and disease. Thus, we aimed to identify potential metabolomic biomarkers related to the NAFLD stage in Argentina, and to assess their relationship with clinical and host genetic factors. Materials and methods: Adult healthy volunteers (HV) and biopsy-proven simple steatosis (SS) or non-alcoholic steatohepatitis (NASH) patients were recruited. Demographic, clinical and food frequency consumption data, as well as plasma and stool samples were collected. SNP rs738409 (PNPLA3 gene) was determined in all volunteers. HPLC and flow injection analysis with MS/MS in tandem was applied for metabolomic studies using the MxP Quant 500 Kit (Biocrates Life Sciences AG, Austria). Significantly different metabolites among groups were identified with MetaboAnalyst v4.0. Bivariate and multivariate analyses were used to identify variables that were independently related to NAFLD stage. Forward stepwise logistic regression models were constructed to design the best feature combination that could distinguish between study groups. Receiver Operating Characteristic (ROC) curves were used to evaluate models′ accuracy. Results: A total of 53 volunteers were recruited: 19 HV, 12 SS and 22 NASH. Diet was similar between groups. The concentration of 33 out of 424 detected metabolites (25 in plasma and 8 in stool) was significantly different among study groups. Levels of triglycerides (TG) were higher among NAFLD patients, whereas levels of phosphatidylcholines (PC) and lysoPC were depleted relative to HV. The PNPLA3 risk genotype for NAFLD and NASH (GG) was related to higher plasma levels of eicosenoic acid FA(20:1) (p<0.001). Plasma metabolites showed a higher accuracy for diagnosis of NAFLD and NASH when compared to stool metabolites. Body mass index (BMI) and plasma levels of PC aa C24:0, FA(20:1) and TG(16:1_34:1) showed high accuracy for diagnosis of NAFLD; whereas the best AUROC for discriminating NASH from SS was that of plasma levels of PC aa C24:0 and PC ae C40:1. Conclusion: A panel of plasma and stool biomarkers could distinguish between NAFLD and NASH in a cohort of patients from Argentina. Plasma biomarkers may be diagnostic in these patients and could be used to assess disease progression. Further validation studies including a larger number of patients are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease in Argentina

Mazzini

Cook²,

Gorcsan³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Age in general also plays a role in GM composition: for instance, the GM of a 70 year old is different from that of an infant, and is characterized primarily by a reduced population of Bifidobacteria and an increased amount of Clostridia [15]. Ethnicity has also been linked to differences in microbiota composition [16], which could explain differences in the incidence of diseases in certain populations, and may even prove effective in terms of disease prevention and treatment [17]. While the aforementioned factors are difficult or impossible to change, one of the main drivers of microbiota composition is represented by diet [18], which can instead be modulated to some extent.…”

Section: Gut Microbiota and Immunitymentioning

confidence: 99%

Gut–Kidney–Heart: A Novel Trilogy

Caldarelli,

Franza,

Rio

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The microbiota represents a key factor in determining health and disease. Its role in inflammation and immunological disorders is well known, but it is also involved in several complex conditions, ranging from neurological to psychiatric, from gastrointestinal to cardiovascular diseases. It has recently been hypothesized that the gut microbiota may act as an intermediary in the close interaction between kidneys and the cardiovascular system, leading to the conceptualization of the “gut–kidney–heart” axis. In this narrative review, we will discuss the impact of the gut microbiota on each system while also reviewing the available data regarding the axis itself. We will also describe the role of gut metabolites in this complex interplay, as well as potential therapeutical perspectives.

show abstract

“…The creation of therapies for focused microbiota modification can be made easier with the help of ethnicity-specific microbial signatures ( Dehingia et al., 2019 ). The core collection database of the Web of Science (WOS) was utilized as the database source, and the world-wide variations in gut microbiota due to ethnicity were examined using CiteSpace 5.8 software.…”

Section: Global Research On the Gut Microbiota Of Ethnic Minoritiesmentioning

confidence: 99%

Progress in research on gut microbiota in ethnic minorities in China and consideration of intervention strategies based on ethnic medicine: A review

Chen

Duan

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

One of the variables affecting gut microbiota is ethnicity. There are 56 ethnic subgroups in China, and their intestinal flora differs. A wealth of medical resources has also been produced by the presence of numerous ethnic minorities. In this study, we reviewed the pertinent literature on the intestinal flora of ethnic minorities in China and abroad using the CiteSpace visualization software, and we used bibliometric techniques to find the most widely prescribed medications for preventing and treating endemic diseases in ethnic minorities. Based on the gut microbiology of minority populations, we suggest that by comprehensive development involving literature, experimental, and clinical research, the pharmacological action mechanisms for interventions in endemic diseases can be drawn from ethnic medicine. This point of view has not been discussed before and will offer a fresh perspective on the creation and application of ethnic medications as well as a fresh method for the management of prevalent diseases in ethnic communities.

show abstract

Ethnicity-Influenced Microbiota: A Future Healthcare Perspective

Cited by 10 publications

References 9 publications

Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease in Argentina

Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease in Argentina

Gut–Kidney–Heart: A Novel Trilogy

Progress in research on gut microbiota in ethnic minorities in China and consideration of intervention strategies based on ethnic medicine: A review

Contact Info

Product

Resources

About